Cogent Biosciences Inc (COGT) FinancialsCOGTCogent Biosciences Inc

Evaluating the bottom line, Cogent Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -129.17%, provide a clear picture of how effectively COGT converts its operational activities into shareholder value.

In the context of the broader market, COGT competes directly with industry leaders such as TLX and CRSP. With a market capitalization of $5.38B, it holds a leading position in the sector. When comparing efficiency, COGT's gross margin of N/A stands against TLX's N/A and CRSP's 100.00%. Such benchmarking helps identify whether Cogent Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Cogent has shown a remarkable 91.36% increase over the past year, despite a year-to-date decline of 10.77%. The company is currently facing significant net losses, with a net income of -88,932,000 USD in Q2 2026.